Refractory Angina Pipeline Insight

DelveInsight’s, “Refractory Angina Pipeline Insight, 2026” report provides comprehensive insights about 3+ companies and 4+ pipeline drugs in Refractory Angina pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Refractory Angina Understanding

Refractory Angina Overview

Refractory angina is a chronic condition characterized by persistent angina (chest pain or discomfort due to myocardial ischemia) that continues despite optimal medical therapy and when conventional revascularization procedures such as percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) are no longer feasible. It is typically associated with advanced Coronary Artery Disease and can significantly impair quality of life. Although the condition is not usually associated with increased mortality compared with other forms of stable coronary artery disease, it often results in recurrent symptoms and frequent healthcare utilization.  The hallmark symptom of refractory angina is chronic chest pain or pressure, often triggered by physical exertion, emotional stress, or even occurring at rest in severe cases. Patients may also experience shortness of breath, fatigue, palpitations, dizziness, nausea, and reduced exercise tolerance. Symptoms persist despite treatment with anti-anginal medications such as nitrates, beta-blockers, and calcium channel blockers, and can substantially limit daily activities.

Refractory angina is most commonly caused by severe, diffuse coronary artery disease that cannot be adequately treated with revascularization procedures. Other contributing factors include microvascular dysfunction, incomplete revascularization, progression of atherosclerosis, chronic total occlusions, and endothelial dysfunction. Risk factors such as diabetes, hypertension, hyperlipidemia, obesity, smoking, and advanced age further contribute to disease progression and symptom persistence. 

Diagnosis is based on a combination of clinical history, symptom assessment, and evidence of myocardial ischemia despite optimal therapy. Diagnostic tools may include electrocardiography (ECG), stress testing, echocardiography, myocardial perfusion imaging, cardiac MRI, coronary CT angiography, and invasive coronary angiography. Physicians also evaluate whether additional revascularization options are feasible before confirming a diagnosis of refractory angina.  Management focuses on symptom relief, improving quality of life, and reducing ischemic burden. Treatment typically includes optimized anti-anginal medications such as nitrates, beta-blockers, calcium channel blockers, and Ranolazine, alongside aggressive management of cardiovascular risk factors. For patients with persistent symptoms, advanced therapies such as enhanced external counterpulsation (EECP), spinal cord stimulation, coronary sinus reduction, stem cell-based therapies, and investigational regenerative approaches may be considered. Lifestyle modifications, cardiac rehabilitation, and psychosocial support also play important roles in long-term management.  

"Refractory Angina Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Refractory Angina pipeline landscape is provided which includes the disease overview and Refractory Angina treatment guidelines. The assessment part of the report embraces, in depth Refractory Angina commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Refractory Angina collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Refractory Angina Pipeline Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Refractory Angina R&D. The therapies under development are focused on novel approaches to treat/improve Refractory Angina.

Refractory Angina Emerging Drugs Analysis

This segment of the Refractory Angina report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, Preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Refractory Angina Emerging Drugs

XC001: XyloCor Therapeutics

XC001 is an investigational gene therapy for the treatment of patients with refractory angina with no treatment options. Patients who have exhausted pharmacologic options and are not eligible for PCI or coronary artery bypass grafts become sedentary because of their symptoms and this can exacerbate comorbidities causing rapid deterioration of their health status and results in a poor quality of life because of the associated chest pain caused by the ischemia when even moderate physical exertion occurs. XC001 is designed to stimulate the formation of new coronary blood vessels to serve areas of the heart that are not receiving adequate blood supply. This treatment strategy is based on both pre-clinical and clinical evidence and should enable the patients to become less limited in their daily activities because of debilitating chest pain. An Investigational New Drug (IND) application for XC001 is open with the FDA. Enrollment in the Refractory Angina trial is complete. Currently, the drug is in Phase II stage of its development for the treatment of refractory angina.

Further product details are provided in the report……..

Refractory Angina Drug Therapeutic Assessment

This segment of the report provides insights about the different Refractory Angina drugs segregated based on following parameters that define the scope of the report, such as:
Major  Players in Refractory Angina
There are approx. 3+ key companies which are developing the therapies for Refractory Angina. The companies which have their Refractory Angina drug candidates in the most advanced stage, i.e. Phase II include, XyloCor Therapeutics

Refractory Angina Clinical Trial Phases

DelveInsight’s report covers around 4+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of 
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Refractory Angina Drug Route of Administration

Refractory Angina pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral 
• Topical

Refractory Angina Product Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer 
• Gene therapy

Refractory Angina Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Refractory Angina Clinical Trial Activities

The Refractory Angina Pipeline report provides insights into different Refractory Angina Clinical Trial within Phase III, II, I, preclinical and discovery stage. It also analyses Refractory Angina therapeutic drugs key players involved in developing key drugs. 

Refractory Angina Pipeline Development Activities

The Refractory Angina Clinical Trial Analysis report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Refractory Angina drugs.

Refractory Angina Pipeline Report Insights

• Refractory Angina Pipeline Analysis
• Refractory Angina Therapeutic Assessment
• Refractory Angina Unmet Needs
• Impact of Refractory Angina Drugs

Refractory Angina Pipeline Report Assessment

• Refractory Angina Pipeline Product Profiles
• Refractory Angina Therapeutic Assessment
• Refractory Angina Pipeline Assessment
• Refractory Angina Inactive drugs assessment
• Refractory Angina Market Unmet Needs

Key Questions Answered In the Refractory Angina Pipeline Report

• Current Treatment Scenario and Emerging Therapies:
• How many companies are developing Refractory Angina drugs?
• How many Refractory Angina drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Refractory Angina?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Refractory Angina therapeutics? 
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies? 
• What are the clinical studies going on for Refractory Angina and their status?
• What are the key designations that have been granted to the emerging drugs?

Refractory Angina Key Players

• XyloCor Therapeutics
• Legend Biotech

Refractory Angina Key Products

• XC001
• LB2102